Article Per Year (5 Year)
p-Index From 2021 - 2026
0.408
P-Index
This Author published in this journals
All Journal Ibnu Sina: Jurnal Kedokteran dan Kesehatan - Fakultas Kedokteran Universitas Islam Sumatera Utara
Ananda, Khairuman Fitrah
Unknown Affiliation
Humanities Health Professions Medicine & Pharmacology Public Health

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
EFFECTIVENESS OF LOW VERSUS HIGH DOSE STATINS FOR REDUCING MAJOR CARDIOVASCULAR EVENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS: EFEKTIVITAS STATIN DOSIS RENDAH DAN TINGGI TERHADAP KEJADIAN KARDIOVASKULAR MAYOR: SUATU TINJAUAN SISTEMATISDAN META-ANALISIS Ananda, Khairuman Fitrah; Sarumpaet, Abigail Christine; Sianturi, Agustina
Ibnu Sina: Jurnal Kedokteran dan Kesehatan - Fakultas Kedokteran Universitas Islam Sumatera Utara Vol. 25 No. 1 (2026): Januari 2026
Publisher : Faculty of Medicine Universitas Islam Sumatera Utara

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.30743/ibnusina.v25i1.981

Abstract

Coronary heart disease (CHD) remains a leading cause of global mortality. Statins are first-line therapy for reducing major adverse cardiovascular events (MACE); however, the optimal dosing strategy remains debated, particularly between ACC/AHA guidelines recommending high-dose statins and ESC guidelines favoring a stepwise approach. Asian populations with SLCO1B1 gene polymorphisms are at increased risk for statin-related adverse effects, such as myopathy and hepatotoxicity. This study aimed to assess the efficacy and safety of high-dose versus low-dose statins in reducing MACE among patients with coronary artery disease (CAD). Methods: A systematic review and meta-analysis were conducted following PRISMA 2020 guidelines. Literature searches were performed in PubMed, Embase, Cochrane Library, and Scopus (2020–2025). Ten studies (n = 43,985) were included in the final analysis. Random-effects meta-analysis was performed using Review Manager 5.4. Funnel plot asymmetry suggested potential publication bias. High-dose statins significantly reduced MACE risk (RR 0.85; p = 0.004) and LDL-C levels, but increased myopathy (OR 2.3) and hepatotoxicity risks, especially in SLCO1B1 polymorphism carriers. Low-dose statins plus ezetimibe achieved comparable LDL-C reduction with fewer adverse events. High-dose statin therapy significantly increased the relative risk of myopathy (OR 2.3; 95% CI 1.8–2.9), particularly in genetically susceptible individuals. Conclusion: High-dose statins improve cardiovascular outcomes but require close monitoring. Low-dose statins with ezetimibe offer a safer alternative, supporting personalized therapy based on genetic and clinical factors.
META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS ON FINERENONE FOR CARDIOVASCULAR OUTCOMES IN TYPE 2 DIABETES AND CHRONIC KIDNEY DISEASE: META-ANALISIS UJI ACAK TERKONTROL FINERENON TERHADAP LUARAN KARDIOVASKULAR PADA DIABETES TIPE 2 DAN PENYAKIT GINJAL KRONIK Ananda, Khairuman Fitrah; Sarumpaet, Abigail Christine; Sianturi, Agustina
Ibnu Sina: Jurnal Kedokteran dan Kesehatan - Fakultas Kedokteran Universitas Islam Sumatera Utara Vol. 25 No. 1 (2026): Januari 2026
Publisher : Faculty of Medicine Universitas Islam Sumatera Utara

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.30743/ibnusina.v25i1.984

Abstract

Patients with chronic kidney disease and type 2 diabetes mellitus are at high risk for cardiovascular events. Finerenone, a non-steroidal mineralocorticoid receptor antagonist, shows potential as an additional therapy with cardioprotective effects. We conducted a meta-analysis based on data from randomized controlled trials by systematically searching the PubMed and ScienceDirect databases, using the PICOS framework: chronic kidney disease and type 2 diabetes mellitus (P); finerenone (I); placebo (C); cardiovascular outcomes (O); and randomized controlled trials (S). We included articles published within the last 10 years and available in full-text format. A total of 4 RCTs were included in this analysis. Statistical analysis was performed using the Random Effect Model. The analysis showed that finerenone reduced the odds of non-fatal myocardial infarction by 9% compared to placebo (OR 0.91; 95% CI: 0.80–1.03) and reduced the risk of hospitalization due to heart failure by 17% (OR 0.73; 95% CI: 0.66–0.82). All statistical results were significant, except for non-fatal myocardial infarction. The heterogeneity level was assessed as low to moderate (I² = 10%, 0%, and 58%). Risk of bias assessment using the RoB-2 tool indicated that all included studies had a low risk of bias. Finerenone demonstrated better outcomes compared to placebo, suggesting its potential benefit in improving cardiovascular outcomes in this population.
Co-Authors Sarumpaet, Abigail Christine Sianturi, Agustina